Reuters logo
BRIEF-Cancer Genetics Q3 loss per share $0.15
November 9, 2017 / 1:22 PM / a month ago

BRIEF-Cancer Genetics Q3 loss per share $0.15

Nov 9 (Reuters) - Cancer Genetics Inc

* Cancer genetics reports record third quarter 2017 revenue and 134% increase in contracted bookings from major biotech and pharmaceutical companies

* Q3 loss per share $0.15

* Q3 revenue $8.0 million versus i/b/e/s view $7.9 million

* Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S

* Cancer genetics inc - ‍integration of vivopharm acquisition is on-track and will deliver a full quarter of results and additional revenue in q4 of 2017​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below